Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Active vitamin D [1,25(OH)2D] levels, slightly increased, without statistically significance, under burosumab treatment: from 48.4 ± 14.2 pg/mL at baseline (n = 14), then 51.4 ± 14.7 (n = 19), 56.7 ± 20.1 (n = 12) and 55.6 ± 9.5 (n = 6) pg/mL at 12, 24 and 36 months, respectively.

Source: Effect of burosumab treatment on metabolic parameters. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All patients were referred to kidney ultrasound before burosumab initiation, every 6 months during the first year of burosumab treatment, and yearly thereafter.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study

Study design awaiting verification · Frontiers in Pediatrics · 2024

Original publication title

Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study

Shelly Levi; Daniel Landau; Miriam Davidovits; Mika Shapira Rootman; Avivit Brener; Shoshana Gal; Yael Borovitz; Ori Goldberg; Rachel Bello; Roxana Cleper; Yael Lebenthal; Yael Levy-Shraga; Dov Tiosano; Adi Chezana; Ravit Regev; Leonid Zeitlin

© 2024 Levi, Landau, Davidovits, Shapira Rootman, Brener, Gal, Borovitz, Goldberg, Bello, Cleper, Lebenthal, Levy-Shraga, Tiosano, Chezana, Regev and Zeitlin.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In children with XLH treated with burosumab, HC was an infrequent side effect and preexisting NC did not worsen.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

X-linked hypophosphatemic rickets (XLH) is associated with uninhibited FGF23 activity, which leads to phosphaturia, hypophosphatemia and depressed active vitamin D (1,25OH2D) levels. Conventional treatment with phosphate supplements and vitamin D analogs may lead to hypercalciuria (HC), nephrocalcinosis (NC) and hyperparathyroidism. We investigated the effects of burosumab treatment, an anti-FGF23 monoclonal antibody recently approved for XLH, on these complications.

Source: Background

Abstract: What methods does the paper describe?

This retrospective study included children with XLH who were treated with burosumab for at least one year at one of three referral centers. Clinical and biochemical potential treatment outcomes were regularly followed, including multiple urine calcium measurements and NC severity score (0 = no NC, 3 = worse NC).

Source: Methods

Abstract: Results

Twenty-six (13 male) children aged 7.6 ± 3.9 years were followed for 27.5 ± 9.6 months. Mean serum phosphate levels rapidly increased from 2.67 ± 0.61 at baseline to 3.57 ± 0.53 mg/dL after 3 months (p < 0.001) and remained stable thereafter. Concomitant decreases were observed in phosphaturia, serum alkaline phosphatase and parathyroid hormone. HC (U-Ca/Cr > 0.2 mg/mg) was detected in 2/26 (7.7%) patients before burosumab initiation, resolved in one and persisted, albeit improved, in the second.

Two patients were newly diagnosed with HC, 15 and 3 months after therapy, which persisted in one of them despite dose reduction attempts. Seven patients had NC at baseline (mean score: 1.8 ± 0.34), but none showed deterioration or developed new NC.

Source: Results

Abstract: Conclusion

In children with XLH treated with burosumab, HC was an infrequent side effect and preexisting NC did not worsen.

Source: Conclusion
Authors’ abstract

Background

X-linked hypophosphatemic rickets (XLH) is associated with uninhibited FGF23 activity, which leads to phosphaturia, hypophosphatemia and depressed active vitamin D (1,25OH2D) levels. Conventional treatment with phosphate supplements and vitamin D analogs may lead to hypercalciuria (HC), nephrocalcinosis (NC) and hyperparathyroidism. We investigated the effects of burosumab treatment, an anti-FGF23 monoclonal antibody recently approved for XLH, on these complications.

Methods

This retrospective study included children with XLH who were treated with burosumab for at least one year at one of three referral centers. Clinical and biochemical potential treatment outcomes were regularly followed, including multiple urine calcium measurements and NC severity score (0 = no NC, 3 = worse NC).

Results

Twenty-six (13 male) children aged 7.6 ± 3.9 years were followed for 27.5 ± 9.6 months. Mean serum phosphate levels rapidly increased from 2.67 ± 0.61 at baseline to 3.57 ± 0.53 mg/dL after 3 months (p < 0.001) and remained stable thereafter. Concomitant decreases were observed in phosphaturia, serum alkaline phosphatase and parathyroid hormone. HC (U-Ca/Cr > 0.2 mg/mg) was detected in 2/26 (7.7%) patients before burosumab initiation, resolved in one and persisted, albeit improved, in the second.

Two patients were newly diagnosed with HC, 15 and 3 months after therapy, which persisted in one of them despite dose reduction attempts. Seven patients had NC at baseline (mean score: 1.8 ± 0.34), but none showed deterioration or developed new NC.

Conclusion

In children with XLH treated with burosumab, HC was an infrequent side effect and preexisting NC did not worsen.

Publication and source details

Original title: Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study

Shelly Levi; Daniel Landau; Miriam Davidovits; Mika Shapira Rootman; Avivit Brener; Shoshana Gal; Yael Borovitz; Ori Goldberg; Rachel Bello; Roxana Cleper; Yael Lebenthal; Yael Levy-Shraga; Dov Tiosano; Adi Chezana; Ravit Regev; Leonid Zeitlin

Frontiers in Pediatrics · 2024

Edited by: Mara Medeiros, Federico Gómez Children's Hospital, Mexico

Reviewed by: Enrique Omar Guadarrama Diaz, National Autonomous University of Mexico, Mexico

Evangelia Kalaitzoglou, University of Kentucky, United States

* Correspondence: Shelly Levi levi.shelly@gmail.com
© 2024 Levi, Landau, Davidovits, Shapira Rootman, Brener, Gal, Borovitz, Goldberg, Bello, Cleper, Lebenthal, Levy-Shraga, Tiosano, Chezana, Regev and Zeitlin.2024Levi, Landau, Davidovits, Shapira Rootman, Brener, Gal, Borovitz, Goldberg, Bello, Cleper, Lebenthal, Levy-Shraga, Tiosano, Chezana, Regev and Zeitlinhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The authors declare that this study received funding from Medison Inc only for support of the publication fee. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:10:59.239869+00:00

DOI: 10.3389/fped.2024.1487890 · PMC11646759